BIRD is building a national database to collect epidemiological data about IBD in Belgium and data on the use of biological therapies in the treatment of IBD.
Therefore, we will be using the UR-CARE platform provided by ECCO (European Crohn´s and Colitis Organisation - ECCO - UR-CARE (ecco-ibd.eu)).
The BIRD Registry will be used to perform retrospective studies and to obtain a comprehensive overview (summary reports) of IBD characteristics/demographics at a national level. As of January 2022, data of more than 1000 patients from 12 centers have already been entered in UR-CARE. In Q1 of 2022, 13 additional centers will collectively join the BIRD registry study. This includes all Belgium academic centers and most major non-academic hospitals in this country.
Logistical support of the setup of the BIRD registry is provided by Galapagos, Pfizer, Abbvie and Janssen.
